Less than 1% to more than 80%. That's the diagnostic target set by a $55 million program that launched this month for coronary microvascular disease in women.
The VISIBLE program, a joint effort between Wellcome Leap, Melinda French Gates' Pivotal, and the British Heart Foundation, is led by interventional cardiologist Dr. Birgit Vogel and structured as a DARPA-style milestone-driven initiative. It's not just a research grant. It's an outcomes bet. And it lands alongside the American Heart Association's $75 million Go Red for Women Fund, which has quietly shifted the AHA from advocacy organization to strategic investor in the women's health space over the past years - most recently backing Ultromics, an AI platform that detects heart failure (HFpEF) that traditional tools miss in up to 64% of cases.
Combined, that's over $130 million from these two initiatives alone, and they're part of a broader shift - more and more funders are paying attention to women's cardiovascular health.
Why Now
There's a clinical reality that makes these bets make sense. Cardiovascular disease remains the leading cause of death for women globally. Nearly 45% of women over 20 are living with some form of it. And yet fewer than half recognize it as their greatest health threat.
But the real failure isn't awareness - it's diagnostic. Traditional imaging and clinical guidelines were built to detect male-pattern disease and simply can't see what's going wrong in many women's hearts. Take angina with no obstructive coronary arteries (ANOCA) as one example: Roughly 700,000 women in the US and Europe undergo invasive coronary angiography each year only to be told their arteries look "normal" - or that their symptoms are anxiety. The downstream costs are staggering - estimated at $750,000 per patient over a lifetime, with half of these women forced to reduce working hours or retire early. And ANOCA is just one condition in a much broader pattern of missed and misdiagnosed cardiovascular disease in women.
So what has changed now? It seems the economics finally became obvious. And when you can actually quantify the cost of missed diagnoses at this scale, the investment case starts to write itself.
Where the Technology Is Actually Moving
But what makes 2026 different from previous years of "women's heart health awareness" isn't just the capital. It's that a diagnostic toolkit is emerging. Rather than covering each company individually, it's more useful to look at where they sit in the pathway from screening to ongoing care, because the real opportunity is in eventually connecting these layers in a meaningful way.
Catching It Before Symptoms Appear
The most compelling near-term play may be the one that requires no new patient behavior at all. Covera Health's newly launched Protect Her platform uses AI to extract cardiovascular signals from imaging women are already getting - analyzing standard mammograms for breast arterial calcification and chest CTs for coronary calcium. It's an elegant approach. Rather than asking women to seek out cardiac screening, it meets them where they already are in the healthcare system.
This is the kind of infrastructure thinking that could genuinely shift population-level detection, assuming it can navigate the regulatory pathway and convince health systems to integrate it into existing workflows. (More on that gap later)
Continuous Monitoring, Designed for Women's Bodies
Once risk is identified, the data gap widens. Traditional cardiac monitoring wasn't designed for women - not for their anatomy, not for their hormonal cycles, and certainly not for the menopausal transition that dramatically reshapes cardiovascular risk.
Two companies are tackling this from different angles. Bloomer Tech is embedding medical-grade sensors into a smart bra, moving cardiac monitoring out of the clinical setting and into daily life with a form factor designed around the female body. Hello Heart is coming at it from the digital tracking and coaching side - and their recently released data is worth paying attention to. Their peer-reviewed study of 48,000 participants found that menopausal women using their AI-driven coaching achieved blood pressure improvements comparable to premenopausal peers, even though they started with higher baseline risk.
That finding matters beyond Hello Heart specifically. The menopause-cardiovascular connection is one of the most under-addressed intersections in women's health. The menopausal transition opens a critical window of cardiovascular vulnerability and is increasingly understood by researchers but barely reflected in clinical practice. Any technology that can demonstrate efficacy specifically during that window is addressing a real gap.
Rethinking How Care Is Delivered
Diagnosing the problem and monitoring it are necessary but not sufficient if the care delivery model itself is broken. Systole Health is making an interesting bet here as they are replacing the standard 18-minute cardiology visit with hour-long sessions led by cardiologists, built around the reality that 90% of women have at least one cardiovascular risk factor. It's a tech-enabled virtual care model, but the real innovation is the time - giving clinicians enough of it to actually address the complexity of women's cardiovascular risk.
AI at the Diagnostic Core
At the foundation of several of these approaches is AI trained to see what human clinicians - working from biased datasets - have historically missed. The AHA's investment in Ultromics is significant here because of how the AI was trained: On patient outcomes rather than physician labels. That distinction matters. If you train a model on what cardiologists have historically flagged, you're encoding decades of gender bias into the algorithm. Training on outcomes sidesteps that entirely.
CorDiFio Health is working a similar angle - an AI-powered platform focused on early identification that aims to bridge what they call the "half-century gap" in gender-based cardiovascular medicine, giving both patients and clinicians data-driven screening tools.
The Hard Questions
Here's where the reality check comes in, because the gap between capital deployed, innovations developed and outcomes achieved in women's health is something we've seen before.
The adoption gap. The VISIBLE program's 1% to 80% diagnostic target is extraordinary, but it's also a reminder that building the technology is only half the battle. We've seen this pattern before in women's health. Innovative tools get developed, but then stall against clinical training that hasn't caught up, referral pathways that don't exist yet, and reimbursement structures that weren't designed for them. Wellcome Leap's funded research program runs for three years. Translating whatever it produces into real-world clinical adoption, however, is a different challenge entirely - and one our industry has yet to consistently crack.
The regulatory question. Several tools currently exist in regulatory grey zones with no FDA clearance or CE mark so far. In many ways the regulatory pathway is as important as the technology itself.
The reimbursement gap. Even if every one of these tools works exactly as promised, who pays? Screening for breast arterial calcification on existing mammograms is clinically efficient but difficult to implement if payers won't reimburse for the additional analysis. The history of digital health is full of brilliant tools that sadly couldn't crack the payment model.
The integration challenge. The most promising aspect of this landscape is its multi-layered nature - screening, monitoring, care delivery, and diagnostic AI all advancing simultaneously. But these layers need to talk to each other. A screening flag from Covera needs to flow into monitoring from Bloomer or Hello Heart, which needs to inform in-person care or care delivery through platforms like Systole. That interoperability barely exists today, and no one company or initiative is building it.
The Bigger Picture
2026 probably isn't the year women's cardiovascular disease gets "solved" - but it might be the year the problem is properly defined and funded in a way that capital markets, health systems, and policymakers can actually act on. That matters more than it sounds.
What's emerging isn't just funding or technology in isolation. It's a diagnostic toolkit that spans the full pathway from screening to monitoring to care delivery. The companies building at each layer are promising. But someone needs to build the connecting tissue between them - and that's where the real infrastructure opportunity lives.
The risks are real. We could end up with beautiful point solutions that never connect into a coherent pathway. Regulatory and reimbursement realities could slow adoption to a crawl. A few years from now, we might be writing another awareness piece instead of tracking outcomes data from innovative solutions. We've seen this pattern before in women's health.
But here's what feels different this time: The money isn't asking for awareness campaigns. It's asking for measurable diagnostic rates - from less than 1% to more than 80%. That shift from awareness to accountability is the kind of conversation that actually changes systems. And it's encouraging to see it happening in our industry right now.
